Clinical significance of coagulation index combined with tumor marker detection in colon cancer

  • SUO Lingyu ,
  • WANG Hailong ,
  • WANG Zhepeng ,
  • ZHENG Liansheng ,
  • ZHANG Qian ,
  • DUAN Shuquan
Expand
  • The Second Affiliated Hospital of Baotou Medical College, Baotou 014030, China

Received date: 2023-06-21

  Online published: 2024-06-24

Abstract

Objective: To detect the expression of coagulation function and tumor markers in patients with colon cancer, and to analyze its relationship with tumor development. Methods: A total of 50 patients with colon cancer diagnosed in the Digestive Minimally Invasive Center of the Second Affiliated Hospital of Baotou Medical College from January 2021 to June 2022 were selected as the observation group, and 50 serum samples with normal results were selected as the control group. The serum tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen-199 (CA-199) and coagulation function related indicators such as prothrombin time (PT) and activated partial prothrombin time (APTT) were detected in the two groups, and the differences in the expression of different indicators between groups and within groups were analyzed. Results: Compared with control group, APTT and PT in observation group were significantly decreased (P<0.05), CEA and CA-199 were significantly increased (P<0.05). In the observation group, compared with different clinical stages (Ⅰ-Ⅱ and Ⅲ-Ⅳ), the time of PT and APTT in Ⅰ-Ⅱ was longer than that in Ⅲ-Ⅳ (P<0.05), and the values of CEA and CA-199 were lower (P<0.05); compared with different differentiation degrees (high-middle differentiation and low differentiation), the time of PT and APTT in high-middle differentiation was longer than that in low differentiation (P<0.05), and the values of CEA and CA-199 were decreased (P<0.05). Conclusion: In patients with colon cancer, tumor markers CEA and CA-199 and coagulation-related indicators APTT and PT are abnormally expressed, and combined detection can provide a basis for clinical diagnosis. At the same time, combined detection can predict the stage and differentiation of colon tumors.

Cite this article

SUO Lingyu , WANG Hailong , WANG Zhepeng , ZHENG Liansheng , ZHANG Qian , DUAN Shuquan . Clinical significance of coagulation index combined with tumor marker detection in colon cancer[J]. Journal of Baotou Medical College, 2024 , 40(6) : 66 -68 . DOI: 10.16833/j.cnki.jbmc.2024.06.012

References

[1] Nfonsam VN,Jecius H,Chen D,et al.Increasing incidence of colon cancer in the young:assessing the tumor biology[J].J Am Coll Surg, 2019, 229(1):79-90.
[2] 韩文峰,张有成.左右半结肠癌病理特征及治疗新策略研究进展[J].中华普通外科学文献(电子版),2019,13(5):408-411.
[3] 许佳义,王金凯,周鲁,等.血清CRP、CA19-9与CEA联合检测对结直肠癌的术前诊断价值[J].宁夏医科大学学报,2017,39(6):641-644,737.
[4] 金静静,周跃,陶运娟.结肠癌患者血清CRP、CEA和CA19-9联合检测的临床意义[J].青岛医药卫生,2022,54(2):93-96.
[5] 胡顺霖,李敏,叶江锋,等.血清肿瘤标志物检测在结肠癌辅助诊断中的价值[J].实用临床医药杂志,2019,23(5):35-37.
[6] 邱智宇,李济宾.结直肠癌筛查方法研究进展[J].肿瘤预防与治疗,2019,32(11):1024-1030.
[7] 刘盛楠,刘瑞,范婷婷,等.结直肠癌的诊断和治疗研究进展[J].山东医药,2017,57(40):110-112.
[8] 陈如昌.联合检验粪便及肿瘤标志物在结、直肠癌诊治中的价值[J].中国卫生检验杂志,2015,25(1):57-59.
[9] 黄远玲,李纯团,王少雄,等.胃癌患者凝血功能、D二聚体、血小板计数的变化与肿瘤临床特征的关系[J].血栓与止血学,2019,25(6):906-908,912.
[10] 阳莎,何佳,陈鸣.结直肠癌患者凝血功能指标和肿瘤标志物与临床病理特征的关系[J]. 国际检验医学杂志,2021,42(3):257-262.
[11] 杨之敏,邱堃,王静.胃癌患者凝血功能与病理特征的关系探讨[J].中国实验诊断学,2016,20(9):1480-1482.
[12] Rong GD,Zhang MJ,Xia WY,et al.Plasma CADM1 promoter hypermethylation and D-dimer as novel metastasis predictors of cervical cancer[J].J Obstet Gynaecol Res, 2019,45(7):1251-1259.
[13] 刘琳,张养民.血清多种肿瘤标志物联合检测对结直肠癌的诊断价值[J].实用癌症杂志,2016,31(6):976-978,982.
[14] 梁巍,胡雨薇,应媛媛.联合检测D-二聚体、糖类抗原-199、癌胚抗原在结直肠癌患者中的临床价值[J].中国实验诊断学,2019,23(1):83-85.
[15] 段丽宁,常宁,赵亚静,等.血清肿瘤标志物联合肝功能指标检测对结肠癌肝转移的诊断价值[J].中华肿瘤防治杂志,2022,29(16):1206-1210.
[16] 王玉颖,朱晓峰,薛玉玲,等.联合检测凝血4项和肿瘤标志物在结直肠癌中的临床意义和诊断价值[J].现代肿瘤医学,2019,27(4):615-618.
[17] Tawil N,Bassawon R,Meehan B,et al.Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles[J].Blood Adv,2021,5(6):1682-1694.
[18] 陈艳,郭俊英,高嫣妮,等.胃癌、肠癌患者凝血参数的应用价值[J].中国医学创新,2020,17(36):1-5.
[19] Farge D,Frere C,Connors JM,et al.2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J].Lancet Oncol,2019,20(10):e566-e581.
[20] Khorana AA,Cohen AT,Carrier M,et al.Prevention of venous thromboembolism in ambulatory patients with cancer[J]. ECMO Open,2020,5(6):e000948.
[21] Dvorak HF.Tumors: wounds that do not heal-a historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting[J].Semin Thromb Hemost,2019,45(6):576-592.
Outlines

/